Drug, Medical Device Companies Worry Comparative Effectiveness Research Will Limit Patient Options
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Medical Devices / Diagnostics; Public Health
Article Date: 15 Apr 2009 - 7:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Drug and medical device companies, along with some members of Congress, have expressed concern that the $1.1 billion for comparative effectiveness research included in the economic stimulus package will yield findings that could be used to limit patients' options, the Wall Street Journal reports.
As part of the stimulus package, NIH and HHS are each set to receive $400 million and the Agency for Healthcare Research and Quality is set to receive $300 million for conducting research comparing the effectiveness of different treatment options as a means to reduce use of wasteful and ineffective treatments. HHS has established an advisory committee to coordinate research and distribute the funds; the committee will hold a meeting on Tuesday to gather public input on how the funds for HHS should be spent. NIH has noted that it will consider funding research that aims to compare the cost-effectiveness of biologic drugs, cancer treatments and preventive measures for chronic diseases.
However, Lori Reilly, vice president for policy and research at the Pharmaceutical Research and Manufacturers of America, said, "We don't want (the research) to be used to deny access to care." Teresa Lee, vice president of the Advanced Medical Technology Association, said using "this research to deny access to appropriate treatments for individual patients with individual medical histories and individual needs should not be the objective." Carolyn Clancy, director of AHRQ, said that "the overarching purpose of the program is to give clinicians and patients information on effectiveness, safety and costs" (Zhang, Wall Street Journal, 4/14).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.
© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/146103.php>
APA
http://www.medicalnewstoday.com/releases/146103.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



